KD/KO Validated

KD/KO Validated

Antibody Catalog number Type Applications
STAT3 10253-2-AP Rabbit Poly ELISA, ChIP, FC, IF, IHC, IP, WB

STAT3, one of the latent cytoplasmic transcription factors, mediates the expression of a broad gene variety in response to cell stimuli, and thus plays a key role in cell growth and apoptosis. While working with Proteintech STAT3 antibodies, Yan and colleagues suggested that cancer-associated fibroblasts (CAFs) may activate the anti-apoptotic STAT3 signaling, and decrease Cisplatin-induced apoptosis, thereby promoting chemoresistance in ovarian cancer.¹ Furthermore, another research group using STAT3 antibodies suggested Arctigenin (Atn) as a promising drug candidate for designing new and effective STAT3 inhibitors.²

Immunofluorescent analysis of HeLa cells using STAT3 antibody

Immunofluorescent analysis of HeLa cells using STAT3 antibody (10253-2-AP) at a dilution of 1:25 and Rhodamine-Goat anti-Rabbit IgG.

 

Related Products

Antibody Catalog number Type Applications
STAT1 - KD/KO Validated 10144-2-AP Rabbit Poly ELISA, FC, IF, IHC, IP, WB
STAT2 16674-1-AP Rabbit Poly ELISA, IHC, IP, WB
STAT3 51076-2-AP Rabbit Poly ELISA, IHC, IP, WB
STAT3 - KD/KO Validated 60199-1-Ig Mouse Mono ELISA, IF, IHC, IP, WB
STAT4 51070-2-AP Rabbit Poly ELISA, IF, IHC, WB
STAT5A 13179-1-AP Rabbit Poly ELISA, FC, IHC, IP, WB
STAT5A 66459-1-Ig Mouse Mono ELISA, WB
STAT5B  12071-1-AP Rabbit Poly ELISA, IF, IHC, IP, WB 
STAT6 51073-1-AP Rabbit Poly ELISA, IF, IHC, WB

 

References

1. Cancer-associated fibroblasts attenuate Cisplatininduced apoptosis in ovarian cancer cells by promoting STAT3 signaling, (PMID: 26826383).

2. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy, (PMID: 27861147).